Mavacamten's Dose‐Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling
Echocardiography · 2026-07 · 43 (7)
DOI: 10.1111/echo.70540 ↗At a glance
Journal article in Echocardiography, published online on 2026-07-16. Written by Binbin Cao and 2 co-authors. Institution: Department of Cardiology, The First Affiliated Hospital of Ningbo University., Ningbo, China. Major MEDLINE topics: Cardiomyopathy, Hypertrophic, Ventricular Remodeling, Uracil, Echocardiography. 30 references. The full text is freely available in PubMed Central. Funded by: Key Technology R&D Program of Ningbo, Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province.
Abstract (original language)
Background
Hypertrophic obstructive cardiomyopathy (HOCM) causes dynamic left ventricular outflow tract (LVOT) obstruction and disabling symptoms; many patients do not respond to conventional agents. Mavacamten, a selective cardiac myosin inhibitor, improves gradients, but the dose–time response in routine practice remains unclear.
Aims
To evaluate longitudinal echocardiographic, biomarker, and safety changes associated with clinically guided mavacamten therapy compared with conventional pharmacotherapy in symptomatic HOCM.
Methods
In this single‐center prospective comparative cohort study, 95 symptomatic HOCM patients were included, of whom 48 received mavacamten and 47 received conventional pharmacotherapy. Mavacamten was initiated at 2.5 mg daily and titrated (2.5–10 mg) based on resting LVOT gradient (LVOTG) and ejection fraction (LVEF). Follow‐up assessments were performed at baseline and at scheduled visits at 3, 6, and 9 months. Longitudinal echocardiographic trajectories were analyzed using observed mean changes with 95% confidence intervals (CIs), and baseline imbalance was assessed using inverse probability weighting. The predefined LVOTG response endpoint was defined as a reduction in resting LVOTG of ≥ 30 mmHg from baseline at the last available follow‐up.
Results
Mavacamten was associated with a downward trajectory in resting LVOTG during follow‐up, whereas the control group remained relatively stable. BNP decreased significantly in the mavacamten group, whereas no significant paired change was observed in the control group. The predefined LVOTG response endpoint was achieved by 9 of 48 patients (18.8%) in the mavacamten group and 1 of 42 patients (2.4%) in the control group (Fisher exact p = 0.0175; OR = 9.46, 95% CI 1.14–78.20). No patient experienced LVEF < 50%.
Conclusions
In symptomatic HOCM, clinically guided mavacamten therapy was associated with reductions in resting LVOT gradient and BNP, while LVEF remained preserved during short‐term follow‐up. These findings support individualized dose titration with echocardiographic monitoring, while dose‐stratified and response analyses should be interpreted cautiously because of limited subgroup sizes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, The First Affiliated Hospital of Ningbo University., Ningbo, China.
- Department of Cardiovascular Surgery, Hospital of Anhui Medical University, Hefei, China.
Funding
- Key Technology R&D Program of Ningbo
- Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province
Cite
APA
Cao, B., Li, Y., & Chen, X. (2026). Mavacamten's Dose‐Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling. Echocardiography, 43(7). https://doi.org/10.1111/echo.70540
Vancouver
Cao B, Li Y, Chen X. Mavacamten's Dose‐Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling. Echocardiography. 2026;43(7). doi:10.1111/echo.70540
BibTeX
@article{Cao2026,
author = {Cao, Binbin and Li, Yuanhong and Chen, Xiaomin},
title = {Mavacamten's Dose‐Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling},
journal = {Echocardiography},
year = {2026},
volume = {43},
number = {7},
doi = {10.1111/echo.70540}
}
EUVIMED